New imaging tracer shows promise for spotting tumors
NCT ID NCT06471712
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 34 times
Summary
This early-phase trial tested a new radioactive imaging agent called 18F-LNC1007 in 8 people—some healthy and some with a few small tumors. The goal was to see how the agent moves through the body, how much radiation it gives off, and if it is safe. Participants had PET/CT scans over about a week, with blood and urine samples collected to track the agent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Precision Molecular Imaging & Theranostics (trading as Melbourne Theranostic Innovation Centre)
Melbourne, Australia
Conditions
Explore the condition pages connected to this study.